Development of rasagiline mesylate loaded solid lipid nanoparticles in a thermosensitive mucoadhesive gel: Formulation design using DoE, in-vitro and ex-vivo characterization

Basit Öğe Kaydı
dc.contributor.authorToksoy, Mahmut Ozan
dc.contributor.authorTirnaksiz, Fahriye Figen
dc.date.accessioned2024-04-24T17:20:23Z
dc.date.available2024-04-24T17:20:23Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractRasagiline mesylate (RM) is a selective irreversible MAO-B inhibitor used in the treatment of Parkinson's disease. This study was designed to prepare and optimize RM loaded solid lipid nanoparticles (RM-SLNs) in a thermosensitive mucoadhesive gel (RM-SLNs-GEL). RM-SLNs were prepared combining Gelucire 50/13 (10%), Labrasol (0.3%) Cremophor RH40 (12%) with a mixing rate and time of 500 rpm, 45 min. Mucoadhesive gels were prepared combining Poloxamer 407 and HPMC E5 (15.5% + 0.25%). Optimized formulation (RM-SLNs-GEL) was evaluated for sol-gel transition temperature, viscosity, mucoadhesive force, particle size and distribution, SEM imaging, in-vitro drug release and ex-vivo drug permeation. It was found that optimal formulation had a suitable gelation temperature at 31 degrees C +/- 0.2 degrees C. It was observed that the system was fluid during nasal application at 25 degrees C and viscous at nasal temperature at 32 degrees C. RM-SLNs-GEL has shown particle size, polydispersity index (PDI), % encapsulation efficiency (EE%); 253 nm, 0.282, 37.8% respectively. Ex-vivo permeation study exposed significant enhancement of permeability of RM-SLNs-GEL across mucosa than RM loaded thermosensitive gel (RM-GEL). Our results show that RM-SLNs-GEL formulation could be a potential drug delivery system for the treatment of Parkinson's disease.en_US
dc.description.sponsorshipGazi University Scientific Research Project [02/2019-13]en_US
dc.description.sponsorshipThis study was supported by Gazi University Scientific Research Project (Project number: 02/2019-13). We thank Pharmactive for providing a sample of Rasagiline mesylate used in this study. We thank Gattefosse (Saint-priest, France) for providing Gelucire 50/13 used in this study.en_US
dc.identifier.doi10.29228/jrp.61
dc.identifier.endpage714en_US
dc.identifier.issn2630-6344
dc.identifier.issue5en_US
dc.identifier.startpage702en_US
dc.identifier.trdizinid489725
dc.identifier.urihttps://doi.org/10.29228/jrp.61
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/489725
dc.identifier.urihttps://hdl.handle.net/11468/19006
dc.identifier.volume25en_US
dc.identifier.wosWOS:000701782800018
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.publisherMarmara Univen_US
dc.relation.ispartofJournal of Research in Pharmacy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRasagiline Mesylateen_US
dc.subjectSolid Lipid Nanoparticleen_US
dc.subjectThermosensitive Mucoadhesive Gelen_US
dc.subjectFull Factorial Designen_US
dc.subjectEx-Vivo Permeationen_US
dc.titleDevelopment of rasagiline mesylate loaded solid lipid nanoparticles in a thermosensitive mucoadhesive gel: Formulation design using DoE, in-vitro and ex-vivo characterizationen_US
dc.titleDevelopment of rasagiline mesylate loaded solid lipid nanoparticles in a thermosensitive mucoadhesive gel: Formulation design using DoE, in-vitro and ex-vivo characterization
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu